Table 3. Sensitivity, specificity, and accuracy of the in-house CBA.
Assay | Definite NMOSD | Sensitivity (95% CI) | Accuracy (95% CI) | High risk NMOSD | Sensitivity (95% CI) | Accuracy (95% CI) | OND | Specificity (95% CI) | |||
---|---|---|---|---|---|---|---|---|---|---|---|
Tested | + | Tested | + | Tested | + | ||||||
In-house CBA | 178 | 142 | 80 (73.1–85.4) | 80 (73.1–85.4) | 63 | 48 | 76 (63.8–86.0) | 76 (63.8–86.0) | 145 | 0 | 100 (97.5–100) |
CBA: cell based assay, CI: confidence interval, NMOSD: neuromyelitis optica spectrum disorder, OND: other neurological diseases.